Skip to content
PubMed This is a summary of 109 peer-reviewed journal articles Updated
Dermatology · Mycosis Fungoides

Mycosis Fungoides and Its Variants: A Patient Guide

At a Glance

Mycosis fungoides is a usually slow-growing skin lymphoma that may remain in the skin for years. Its specific variant and stage help guide care, from skin-directed treatments for early disease to systemic therapies for more advanced or blood-involved disease.

Mycosis Fungoides (MF) is the most common form of cutaneous T-cell lymphoma, a rare condition where specific white blood cells called T-cells become cancerous and settle in the skin [1]. Despite the frightening “lymphoma” label, classic MF is typically an indolent, or slow-moving, disease that remains confined to the skin for many years or even decades. It often begins as flat, scaly patches or slightly raised plaques that can be mistaken for common skin issues like eczema or psoriasis. This “great mimicry” is why the journey to a diagnosis often involves multiple biopsies and a long period of observation by specialists who look for the subtle microscopic signatures of the disease [2][3].

Once a diagnosis is confirmed, your medical team uses the TNMB staging system—evaluating the skin (T), lymph nodes (N), internal organs (M), and blood (B)—to map out how much of your body is involved [4]. While most people have early-stage disease that is limited to the skin, some may have variants that behave slightly differently. These include Folliculotropic MF, which affects the hair follicles; Pagetoid Reticulosis, which often appears as a single localized patch; and the extremely rare Granulomatous Slack Skin. Understanding your specific stage and variant is the first step in moving from uncertainty toward a structured management plan [5][6].

What Happens Next?

If you have just been diagnosed, your path will typically involve a baseline examination and staging when indicated, a treatment discussion to weigh your options, and a schedule for follow-up.

The approach to treatment is usually “stage-based,” focusing on the least intensive therapy needed to control the disease. For those in early stages, care centers on skin-directed therapies like specialized light treatments (phototherapy), medicated gels, or localized radiation [7]. If the disease becomes more advanced or involves the blood, systemic therapies—including targeted biologics and immune-modulating treatments—are used to reach cancer cells throughout the body [8]. Because MF is a chronic condition, treatments are often cycled over time to maintain a high quality of life and minimize side effects [9].

Living with MF requires a mindset of long-term vigilance rather than immediate emergency. Routine monitoring and proactive skin care are the foundations of long-term health, allowing you and your doctors to catch any changes early and adjust treatments as needed [10]. While a diagnosis of skin lymphoma is a major life event, most patients find that with consistent care and specialized management—led by a dermatologist or hematologist experienced in cutaneous lymphomas—they can lead full lives while successfully managing the condition as a chronic illness [11].

Common questions in this guide

What is mycosis fungoides, and why can it look like eczema?
Mycosis fungoides is the most common form of cutaneous T-cell lymphoma, a cancer in which certain white blood cells collect in the skin. It often starts as flat, scaly patches or raised plaques that can resemble eczema or psoriasis, so diagnosis may require multiple biopsies and specialist review.
Which variants of mycosis fungoides might I have?
The variants discussed include folliculotropic mycosis fungoides, which affects hair follicles; Pagetoid Reticulosis, which often appears as one localized patch; and Granulomatous Slack Skin, an extremely rare form. Examination, biopsy findings, and the overall pattern of skin involvement help specialists identify the form.
How is mycosis fungoides staged?
The TNMB staging system records how much disease is present in the skin, lymph nodes, internal organs, and blood. Your stage helps the medical team choose a treatment plan and decide how closely to monitor you.
What treatments are used for mycosis fungoides?
Treatment is usually chosen by stage and aims to use the least intensive option that controls the disease. Early mycosis fungoides may be treated with skin-directed options such as phototherapy, medicated gels, or localized radiation, while more advanced or blood-involved disease may need systemic targeted biologic or immune-modulating therapy.
Can people live with mycosis fungoides for many years?
Mycosis fungoides is often a chronic, slow-moving condition, and classic disease can remain limited to the skin for many years. Regular follow-up, proactive skin care, and specialized management help doctors detect changes early, adjust treatment, and support a good quality of life.
How often will I need follow-up for mycosis fungoides?
Your dermatologist or hematologist will set the follow-up schedule based on your disease stage, variant, and treatment plan. Visits are used to monitor the skin and other areas when indicated, look for changes, and adjust care if needed.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on mycosis fungoides variant.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my diagnosis considered 'classic' Mycosis Fungoides, or do I have a specific variant like the folliculotropic type?
  2. 2.Based on my initial skin examination and biopsy, what is my current TNMB stage?
  3. 3.Are we starting with skin-directed treatments, and what signs of improvement should I look for over the next few months?
  4. 4.How often will I need to return for monitoring to ensure the disease is not progressing?

References

References (11)
  1. 1

    High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides.

    de Masson A, O'Malley JT, Elco CP, et al.

    Science translational medicine 2018; (10(440)) doi:10.1126/scitranslmed.aar5894.

    PMID: 29743350
  2. 2

    Reflectance confocal microscopy as a first-line diagnostic technique for mycosis fungoides.

    Yeager DG, Noor O, Rao BK

    Cutis 2018; (102(1)):56-58.

    PMID: 30138497
  3. 3

    When mycosis fungoides seems not to be within the spectrum of clinical and histopathological differential diagnoses.

    Di Prete M, Michelerio A, Lora V, et al.

    Dermatology reports 2024; (16(Suppl 2)):10008 doi:10.4081/dr.2024.10008.

    PMID: 39295886
  4. 4

    Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force.

    Scarisbrick JJ, Hodak E, Bagot M, et al.

    European journal of cancer (Oxford, England : 1990) 2018; (93()):47-56 doi:10.1016/j.ejca.2018.01.076.

    PMID: 29477101
  5. 5

    Cicatricial Alopecia Related to Folliculotropic Mycosis Fungoides.

    Kreutzer KM, Effendy I

    Dermatology and therapy 2020; (10(5)):1175-1180 doi:10.1007/s13555-020-00429-0.

    PMID: 32833161
  6. 6

    Woringer-Kolopp disease (localized pagetoid reticulosis): a systematic review.

    Osto M, Afify O, Musa A, et al.

    International journal of dermatology 2023; (62(3)):312-321 doi:10.1111/ijd.16224.

    PMID: 35485962
  7. 7

    New developments in skin-directed treatments of cutaneous T-cell lymphoma.

    Amitay-Laish I, Hodak E

    Presse medicale (Paris, France : 1983) 2022; (51(1)):104125 doi:10.1016/j.lpm.2022.104125.

    PMID: 35562084
  8. 8

    Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management.

    Hristov AC, Tejasvi T, Wilcox RA

    American journal of hematology 2023; (98(1)):193-209 doi:10.1002/ajh.26760.

    PMID: 36226409
  9. 9

    EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2023.

    Latzka J, Assaf C, Bagot M, et al.

    European journal of cancer (Oxford, England : 1990) 2023; (195()):113343 doi:10.1016/j.ejca.2023.113343.

    PMID: 37890355
  10. 10

    Staging lymph nodes and blood at diagnosis in mycosis fungoides identifies patients at increased risk of progression to advanced stage: A retrospective cohort study.

    Allen PB, McCook-Veal AA, Switchenko JM, et al.

    Cancer 2023; (129(4)):541-550 doi:10.1002/cncr.34579.

    PMID: 36523150
  11. 11

    Screening for second malignancies in mycosis fungoides: non-Hodgkin lymphoma, Hodgkin lymphoma, lung cancer, bladder cancer and melanoma.

    Goyal A, O'Leary D, Goyal K, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2021; (35(9)):1821-1829 doi:10.1111/jdv.17384.

    PMID: 34013554

This page is for informational purposes only and does not constitute medical advice. It provides general information about mycosis fungoides variants, staging, and treatment; your dermatologist or hematology team should interpret your diagnosis and plan your care.